Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

This study has been completed.
Sponsor:
Collaborator:
SCRI Development Innovations, LLC
Information provided by (Responsible Party):
MEI Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT01401868
First received: July 22, 2011
Last updated: June 20, 2013
Last verified: June 2013
  Purpose

The purpose of this study is to determine the tolerability of ME-143, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.


Condition Intervention Phase
Solid Tumors
Drug: ME-143
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 as a Single Agent in Patients With Refractory Solid Tumors

Resource links provided by NLM:


Further study details as provided by MEI Pharma, Inc.:

Primary Outcome Measures:
  • Dose limiting toxicity [ Time Frame: within the first 28 day cycle ] [ Designated as safety issue: No ]
    Patients will be administered ME-143 IV infusions weekly and assessed by physical exam, vital signs, hematology and clinical chemistry, urinalysis and pharmacokinetic sampling.


Secondary Outcome Measures:
  • Response rate [ Time Frame: baseline and a minimum of every 12 weeks ] [ Designated as safety issue: No ]
    radiologic assessments will be performed at baseline and a minimum of every 12 weeks


Enrollment: 18
Study Start Date: September 2011
Study Completion Date: January 2013
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: single arm
dose escalation
Drug: ME-143

experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.

Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.

Other Names:
  • open label
  • single agent

Detailed Description:

The purpose of this study is to determine the tolerability of ME-143, find the maximum tolerated dose, dose limiting toxicities, and the safety profile in patients with refractory solid tumors. In addition, the study is planned to characterize the pharmacokinetic profile of ME-143 and describe any clinical anti-tumor activity observed in patients.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of informed consent
  • Male or female ≥18 years of age
  • Histologic or cytologic confirmed locally advanced or metastatic cancer that has no standard therapeutic alternatives.
  • ECOG Performance status 0-1
  • A minimum life expectancy of 12 weeks
  • Adequate bone marrow, hepatic and renal function as evidenced by

    • Absolute neutrophil count (ANC) > 1.5 x 109/L
    • Platelet count > 100 x 109/L
    • Hemoglobin > 9.0 g/dL
    • Serum bilirubin < 1.5 x ULN
    • AST/ALT (SGOT/SGPT) < or = 2.5 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases
    • Serum creatinine < or = 1.5 x ULN
    • Follicle-Stimulating Hormone (FSH) within normal baseline levels
    • Male patients should have a detectable level of testosterone
  • Female patients who are known to be capable of conception should have a negative serum pregnancy test (beta-human chorionic gonadotropin β-hCG]) within 1 week of starting the study.
  • All potentially fertile patients will agree to use an effective form of contraception during the study and for 90 days following the last dose of ME-143 (an effective form of contraception is defined as an oral contraceptive or a double barrier method).
  • At least 4 weeks must have elapsed prior to Day 1 Cycle 1 since prior chemotherapy (6 weeks for carmustine or mitomycin C), investigational drug or biologic therapy and any toxicity associated with these treatments has recovered to ≤ NCI-CTCAE Grade 1.
  • At least 21 days must have elapsed prior to Day 1 Cycle 1, radiotherapy (limited palliative radiation is allowed > 2 weeks), immunotherapy or following major surgery and any surgical incision should be completely healed

Exclusion Criteria:

  • Patients who are pregnant or breastfeeding
  • Tumor involvement of the Central Nervous System (CNS) Patients with treated and stable CNS metastases may be eligible to participate after discussion and approval from the Medical Monitor
  • Uncontrolled infection or systemic disease.
  • Clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g. angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months.
  • Patients with QTc of > 470 msec on screening ECG. (If a patient has QTc interval >470 msec on screening ECG, the screening ECG may be repeated twice (at least 24 hours apart). The average QTc from the 3 screening ECGs must be <470 msec in order for the patient to be eligible for the study.
  • Any major surgery, radiotherapy, or immunotherapy within the last 21 days (limited palliative radiation is allowed > 2 weeks).
  • Chemotherapy regimens with delayed toxicity within the last 4 weeks (or within 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a weekly basis with limited potential or delayed toxicity within the last 2 weeks.
  • No concurrent systemic chemotherapy or biologic therapy is allowed.
  • Known hypersensitivity to any components of ME-143 study drug product.
  • Known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both).
  • History of solid organ transplantation.
  • Psychiatric disorder or social or geographic situation that would preclude study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01401868

Locations
United States, Oklahoma
Oklahoma University Cancer Institute
Oklahoma City, Oklahoma, United States, 73104
United States, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
MEI Pharma, Inc.
SCRI Development Innovations, LLC
Investigators
Study Chair: Robert D Mass, MD MEI Pharma, Inc.
  More Information

Additional Information:
No publications provided

Responsible Party: MEI Pharma, Inc.
ClinicalTrials.gov Identifier: NCT01401868     History of Changes
Other Study ID Numbers: ME-143-001
Study First Received: July 22, 2011
Last Updated: June 20, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by MEI Pharma, Inc.:
solid tumor
recurrent
advanced
metastatic

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on July 26, 2014